The latest surge has come from Belgian retail response to an announcement that the company will continue to develop its organ transplantation drug tolerimab following some promising studies in rhesus monkeys.

The buying binge showed that European investors (at least those in Belgium) are still willing to drive up prices on early-stage research news.